Supportive Care in Cancer

, Volume 19, Issue 3, pp 425–430

Zoledronic acid and atrial fibrillation in cancer patients

  • Cagatay Arslan
  • Sercan Aksoy
  • Omer Dizdar
  • Didem S. Dede
  • Hakan Harputluoglu
  • Kadri Altundag
Original Article

Abstract

Background and purpose

Treatment with a bisphosphonate was found to be associated with a significantly increased risk for atrial fibrillation (AF) in a few studies. A recent study showed that once-yearly infusions of intravenous zoledronic acid (ZA) significantly increased the risk of serious AF in postmenopausal women with osteoporosis. This study was conducted to determine the frequency of atrial fibrillation among cancer patients receiving the standard treatment of ZA.

Methods

Patients with bone metastases who presented to our outpatient clinic for any reason (routine control, chemotherapy, or ZA administration) were included in the study. All patients had been receiving 4 mg ZA at 4-week intervals, with each dose administered over 15 min. A short survey was completed and standard 12-lead ECG recordings were obtained.

Results

One hundred and twenty-four cancer patients with documented bone metastases were evaluated. Mean age of the patients was 55 ± 13.0 years, 60% of the patients were female. Forty-one percent of the patients had breast cancer, 18% had non-small cell lung cancer, and the remainder had other solid tumors. Mean duration of ZA administration was 13.4 ± 15.0 months. Mean total cumulative dose was 54 ± 15.0 mg per patient. Sixty patients (48%) had previously been treated with anthracycline-containing regimens, and 37 (30%) had received chest radiotherapy that might affect the heart. Twenty-three percent of the patients had hypertension, 10% had diabetes mellitus, 3.7% had myocardial infarction history, 1.9% had congestive heart failure, and 1% had valvular disease; 10.5% were current smokers and 32% ex-smokers. On ECG evaluation, we observed normal sinus rhythm in 58%, sinus tachycardia in 15%, sinus bradicardia in 3.2%, and ventricular extrasystole in 5.7% of the patients. There was no AF in any of the cases.

Conclusions

There was no increase in the risk of AF frequency in cancer patients who were treated with intravenous ZA, although most of the patients had additional risk factors including previous treatment with cardiotoxic agents or with chest radiotherapy. We believe that the risk of AF is negligible in this patient population and does not affect treatment decisions.

Keywords

Zoledronic acid Side effect Arrhythmias Atrial fibrillation Cancer 

References

  1. 1.
    Abrahamsen B, Eiken P, Brixen K (2009) Atrial fibrillation in fracture patients treated with oral bisphosphonates. J Intern Med 265:581–592PubMedCrossRefGoogle Scholar
  2. 2.
    Heckbert SR, Li G, Cummings SR et al (2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826–831PubMedCrossRefGoogle Scholar
  3. 3.
    Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRefGoogle Scholar
  4. 4.
    Ibrahim A, Scher N, Williams G et al (2003) Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 9:2394–2399PubMedGoogle Scholar
  5. 5.
    Woolf AD, Akesson K (2003) Preventing fractures in elderly people. Bmj 327:89–95PubMedCrossRefGoogle Scholar
  6. 6.
    Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809PubMedCrossRefGoogle Scholar
  7. 7.
    Sorensen HT, Christensen S, Mehnert F et al (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. Bmj 336:813–816PubMedCrossRefGoogle Scholar
  8. 8.
    Huang WF, Tsai YW, Wen YW et al (2009) Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene. Menopause 17:57–63CrossRefGoogle Scholar
  9. 9.
    Grosso A, Douglas I, Hingorani A et al (2009) Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 4:e4720PubMedCrossRefGoogle Scholar
  10. 10.
    Bunch TJ, Anderson JL, May HT et al (2009) Relation of bisphosphonate therapies and risk of developing atrial fibrillation. Am J Cardiol 103:824–828PubMedCrossRefGoogle Scholar
  11. 11.
    Wolf PA, Abbott RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22:983–988PubMedGoogle Scholar
  12. 12.
    Kannel WB, Abbott RD, Savage DD, McNamara PM (1983) Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J 106:389–396PubMedCrossRefGoogle Scholar
  13. 13.
    Benjamin EJ, Levy D, Vaziri SM et al (1994) Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. Jama 271:840–844PubMedCrossRefGoogle Scholar
  14. 14.
    Lainscak M, Dagres N, Filippatos GS et al (2008) Atrial fibrillation in chronic non-cardiac disease: where do we stand? Int J Cardiol 128:311–315PubMedCrossRefGoogle Scholar
  15. 15.
    Guzzetti S, Costantino G, Vernocchi A et al (2008) First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation. Intern Emerg Med 3:227–231PubMedCrossRefGoogle Scholar
  16. 16.
    Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867PubMedCrossRefGoogle Scholar
  17. 17.
    Chung MK, Martin DO, Sprecher D et al (2001) C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104:2886–2891PubMedCrossRefGoogle Scholar
  18. 18.
    Guzzetti S, Costantino G, Fundaro C (2002) Systemic inflammation, atrial fibrillation, and cancer. Circulation 106:e40, author reply e40PubMedCrossRefGoogle Scholar
  19. 19.
    Wu FP, Sietses C, von Blomberg BM et al (2003) Systemic and peritoneal inflammatory response after laparoscopic or conventional colon resection in cancer patients: a prospective, randomized trial. Dis Colon Rectum 46:147–155PubMedCrossRefGoogle Scholar
  20. 20.
    Siu CW, Tung HM, Chu KW et al (2005) Prevalence and predictors of new-onset atrial fibrillation after elective surgery for colorectal cancer. Pacing Clin Electrophysiol 28(Suppl 1):S120–123PubMedCrossRefGoogle Scholar
  21. 21.
    Rugo HS (2004) Paraneoplastic syndromes and other non-neoplastic effects of cancer. In: Goldman L, Ausiello D (eds) Cecil textbook of medicine, 22nd edn. Saunders, Philedelphia, pp 1124–1131Google Scholar
  22. 22.
    van der Hooft CS, Heeringa J, van Herpen G et al (2004) Drug-induced atrial fibrillation. J Am Coll Cardiol 44:2117–2124PubMedCrossRefGoogle Scholar
  23. 23.
    van der Hooft CS, Heeringa J, Brusselle GG et al (2006) Corticosteroids and the risk of atrial fibrillation. Arch Intern Med 166:1016–1020PubMedCrossRefGoogle Scholar
  24. 24.
    de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M (2009) Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol 4:77–88PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Cagatay Arslan
    • 1
  • Sercan Aksoy
    • 1
  • Omer Dizdar
    • 1
  • Didem S. Dede
    • 1
  • Hakan Harputluoglu
    • 1
  • Kadri Altundag
    • 1
  1. 1.Department of Medical OncologyHacettepe University Institute of OncologySihhiyeTurkey

Personalised recommendations